Pages that link to "Q43717192"
Jump to navigation
Jump to search
The following pages link to Varied differentiation responses of human leukemias to bryostatin 1. (Q43717192):
Displaying 10 items.
- Protein kinase C targeting in antineoplastic treatment strategies (Q33832628) (← links)
- Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. (Q34549158) (← links)
- A phase I study of intravenous bryostatin 1 in patients with advanced cancer (Q34729529) (← links)
- Review of survival analyses published in cancer journals (Q36081455) (← links)
- A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. (Q36081460) (← links)
- Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply (Q36135273) (← links)
- A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer. (Q36671270) (← links)
- Phorbol ester and bryostatin effects on growth and the expression of oestrogen responsive and TGF-beta 1 genes in breast tumour cells (Q41164898) (← links)
- Stimulation of phosphatidylcholine synthesis by activators of protein kinase C is dissociable from increased phospholipid hydrolysis (Q42829682) (← links)
- Different biological effects of the two protein kinase C activators bryostatin-1 and TPA on human carcinoma cell lines (Q72805213) (← links)